Dr. Laura Esserman knows: A clinical trial is only as good as the feedback you get from patients, and the feedback is only as good as the patients you get to enroll in the trial. So in her groundbreaking
breast cancer screening study, the renowned oncologist and researcher at the University of California, San Francisco, and her team are reaching out to get the best cross-section of women enrolled in her 100,000-woman study. It’s not something, she’s learned, to be left to chance. The study, which Esserman launched in 2016 to test a personalized approach to screening over five years compared to annual mammograms, employs a mix of measures to attract and retain women, especially women of color.
— Women Informed to Screen Depending On Measures of risk — has enrolled 45,000 women ages 40-74. The study puts women in one of two groups: those receiving standard annual mammograms and those whose screening schedules are based on their risk of getting breast cancer, which remains the second-leading cause of cancer death among women. The personalized approach takes into account genetic risk factors assessed from a saliva test from Burlingame’s Color Health Inc.
organizers created an advisory board, including Black breast cancer survivors, women of color from health care organizations and patient advocates, to help reshape the study’s outreach. representatives showed up at health fairs and other local events, the study launched a blog, they created ambassador workshops to engage the Black community and, once women are enrolled, participants can attend a monthly webinar that includes information about breast cancer and a time to offer feedback about the trial. Black women now represent about 10% of new enrollees in the study, which is backed by the Robert Wood Johnson Foundation, Salesforce Inc.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Fonte: denverpost - 🏆 13. / 72 Consulte Mais informação »